Details of the Drug Reposition

General Information of This Drug (ID: DM1N62C)

Drug Name
Quetiapine   DM1N62C
Synonyms
quetiapine; 111974-69-7; Quetiapine [INN:BAN]; UNII-BGL0JSY5SI; BGL0JSY5SI; CHEMBL716; 2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol; CHEBI:8707; C21H25N3O2S; URKOMYMAXPYINW-UHFFFAOYSA-N; 2-(2-(4-Dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)ethanol; Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-; NCGC00095911-03; Co-Quetiapine; Norsic; Quetiapina; Quetiapinum; Quetiapine hemifumarate; Ketipinor (TN); Norsic (TN); Quetiapine (INN); Seroquel (Fumarate); Seroquel (TN); 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethoxy]ethanol; 2-{[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethyl]oxy}ethanol; PD-172760
Therapeutic Class
Antipsychotic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
9 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Delirium DIS2OKP1 N.A. Approved [1]
Bipolar I disorder DISD09EH N.A. Approved [1]
Bipolar depression DISA75FU N.A. Approved [1]
Schizophrenia DISSRV2N 6A20 Approved [2]
Schizoaffective disorder DISLBW6B 6A21 Approved [1]
Bipolar disorder DISAM7J2 6A60 Approved [1]
Major depressive disorder DIS4CL3X 6A70.3 Approved [1]
Anorexia nervosa cachexia DISFO5RQ 6B80 Approved [1]
Methamphetamine dependence DIS1UU1B 6C46.2 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Indications(s)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Alcohol dependence DIS4ZSCO 6C40.2 Phase 3 [3]
------------------------------------------------------------------------------------
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Generalized anxiety disorder DISPSQCW 6B00 Discontinued in Phase 3 [4]
------------------------------------------------------------------------------------

References

1 Quetiapine FDA Label
2 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
3 ClinicalTrials.gov (NCT02362412) Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes. U.S. National Institutes ofHealth.
4 Assessing the Safety/Efficacy of Asacol Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis